Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants Antibodies MonoclonalAntibodies SARSCoV2 COVID19 Omicron Variant NIAIDNews
By Dr. Chinta SidharthanNov 3 2022Reviewed by Aimee Molineux In a recent study published in Cell Reports, researchers generated and characterized two monoclonal antibodies that target the receptor binding domain of the severe acute respiratory syndrome coronavirus 2 spike protein and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.
Current therapeutic monoclonal antibodies also exhibit reduced efficacy against these subvariants, highlighting the need for more effective antibody therapies to tackle the emergent Omicron subvariants. Neutralization assays using pseudotyped viruses were performed to evaluate the selected monoclonal antibodies. The specificity of the monoclonal antibodies towards the receptor binding domain of the spike protein was tested using competition ELISA. The study also tested the neutralizing ability of the monoclonal antibodies against WA-1, the North American founder strain, and other relevant variants of concern.
Results The results reported that NA8 and NE12 have complementary properties, and exhibited potent neutralizing action against all the major SARS-CoV-2 variants of concern. The NA8 monoclonal antibody displayed broad neutralizing abilities at picomolar concentrations against the Beta variant and Omicron BA.1 and BA.2 subvariants, and at nanomolar concentrations against the recent BA.2.12.1 and BA.4 subvariants.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SARS-CoV-2 infections may induce neuroinflammationSARS-CoV-2 infections may induce neuroinflammation ucdavis CellPressNews SARSCoV2 COVID19 Neuroinflammation Infection
Read more »
Frontiers | SARS-CoV-2 specific antibody trajectories in mothers and infants over two months following maternal infectionInfants exposed to caregivers infected with SARS-CoV-2 may have heightened infection risks relative to older children due to their more intensive care and feeding needs, and may experience more severe infection due to their less developed immune systems. However, there has been limited research on COVID-19 outcomes in exposed infants beyond the neonatal period. Between June 2020 – March 2021, we conducted interviews and collected capillary dried blood from SARS-CoV-2 infected mothers and their infants (aged 1-36 months) for up to two months following maternal infection onset (COVID+ group, 87% breastfeeding, n dyads=46 dyads). Comparative data were also collected from breastfeeding mothers with no known SARS-CoV-2 infection or exposures (breastfeeding control group, n dyads=26), and mothers who tested SARS-CoV-2 negative after experiencing symptoms or close contact exposure (COVID- group, n dyads=11, 73% breastfeeding). Dried blood samples were assayed for anti-SARS-CoV-2 S-RBD IgG and IgA positivity and anti-SARS-CoV-2 S1 + S2 IgG concentrations. Within the COVID+ group, the mean probability of seropositivity among infant samples was significantly lower than that of corresponding maternal samples (IgG 0.54 vs. 0.87; IgA 0.33 vs. 0.85), with likelihood of infant infection positively associated with the number of maternal symptoms and other household infections reported. COVID+ mothers reported a lower incidence of COVID-19 symptoms among their infants as compared to themselves and other household adults, and infants had similar PCR positivity rates as other household children. No samples returned by COVID- mothers or their infants tested antibody positive. Among the breastfeeding control group, 44% of mothers but none of their infants tested antibody positive in at least one sample. Results support previous research demonstrating minimal risks to infants following maternal COVID-19 infection, including for breastfeeding infants.
Read more »
Scientists identify a cryptic SARS-CoV-2 lineage in wastewaterIn a recent study posted to the medRxiv* preprint server, researchers in the United States investigated the source of an enigmatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)-like spike (S) protein strain detected in wastewater but not in clinical samples.
Read more »
Vimentin is an important co-receptor for SARS-CoV-2 infectionVimentin is an important co-receptor for SARS-CoV-2 infection Receptor SARSCoV2 Coronavirus Disease COVID ACE2 Vimentin iScience_CP IHU_Marseille univamu
Read more »
Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariantsResearchers at Emory University, Stanford University, and the National Institute of Allergy and Infectious Diseases evaluated whether bivalent coronavirus disease 2019 (COVID-19) boosters conferred protection against new Omicron subvariants.
Read more »
Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variantsScientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants Antibody SARSCoV2 Coronavirus Disease COVID biorxivpreprint WeillCornell UWMadison scrippsresearch UChicago IcahnMountSinai seattlechildren
Read more »